Immunosuppressive glycoforms of soluble CD52

Leonard Charles Harrison; Esther Bandala-Sanchez; Ethan David Goddard-Borger; Nicolle Hannah Packer; Shathili Abdulrahman Mansour

Immunosuppressive glycoforms of soluble CD52

Leonard Charles Harrison (Inventor), Esther Bandala-Sanchez (Inventor), Ethan David Goddard-Borger (Inventor), Nicolle Hannah Packer (Inventor), Shathili Abdulrahman Mansour (Inventor)

Research output: Patent

Abstract

The present disclosure relates to glycoprotein CD52 and fusion proteins thereof, wherein the CD52 glycoprotein has α-2,3-sialylated N-glycans, O-glycosylation and a pI of about 5 to about 6. The disclosure further relates to the preparation and purification of these proteins and their use in the suppression of effector T-cell function and/or immune response, such as in the treatment of diseases or conditions mediated by effector T-cell function.

Original language	English
Patent number	EP3935073
IPC	C07K 9/00,A61K 38/00,A61K 38/04,A61P 37/00,C07K 1/18,C07K 1/22
Priority date	7/03/19
Publication status	Submitted - 12 Jan 2022

Bibliographical note

Designated States:
AL, AT, BA, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

Access to Document

https://patentscope.wipo.int/search/en/detail.jsf?docId=EP347854823

Immunosuppressive glycoforms of soluble CD52
Harrison, L. C. (Inventor), Bandala Sanchez, E. (Inventor), Goddard-Borger, E. D. (Inventor), Packer, N. H. (Inventor) & Mansour, S. A. (Inventor), 16 Jun 2022, (Submitted) IPC No. C07K 14/705, A61K 38/17, A61K 35/16, A61K 38/28, Patent No. US2022185864, Priority date 7 Mar 2019, Priority No. WO2019AU50197
Research output: Patent
Immunosuppressive glycoforms of soluble CD52
Harrison, L. C. (Inventor), Bandala-Sanchez, E. (Inventor), Goddard-Borger, E. D. (Inventor), Packer, N. H. (Inventor) & Shathili, A. (Inventor), 19 Mar 2020, IPC No. C07K 4/12, A61K 38/00, A61K 38/10, A61K 39/00, A61P 29/00, A61P 37/00, Patent No. AU2019201584, 7 Mar 2019, Priority date 7 Mar 2019
Research output: Patent
Immunosuppressive glycoforms of soluble CD52
Harrison, L. C. (Inventor), Bandala-Sanchez, E. (Inventor), Goddard-Borger, E. D. (Inventor), Packer, N. H. (Inventor) & Mansour, S. A. (Inventor), 10 Sept 2020, (Submitted) IPC No. C07K 9/00 2006.1, C07K 1/22 2006.1, C07K 1/18 2006.1, A61P 37/00 2006.1, A61K 38/04 2006.1, Patent No. WO2020176921, Priority date 7 Mar 2019, Priority No. WO2019AU50197
Research output: Patent

Cite this

@misc{0a9aaedde12346a8a978dbbe8dda6dc9,

title = "Immunosuppressive glycoforms of soluble CD52",

abstract = "The present disclosure relates to glycoprotein CD52 and fusion proteins thereof, wherein the CD52 glycoprotein has α-2,3-sialylated N-glycans, O-glycosylation and a pI of about 5 to about 6. The disclosure further relates to the preparation and purification of these proteins and their use in the suppression of effector T-cell function and/or immune response, such as in the treatment of diseases or conditions mediated by effector T-cell function.",

author = "Harrison, \{Leonard Charles\} and Esther Bandala-Sanchez and Goddard-Borger, \{Ethan David\} and Packer, \{Nicolle Hannah\} and Mansour, \{Shathili Abdulrahman\}",

note = "Designated States: AL, AT, BA, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR; EP3935073; C07K 9/00,A61K 38/00,A61K 38/04,A61P 37/00,C07K 1/18,C07K 1/22",

year = "2022",

month = jan,

day = "12",

language = "English",

type = "Patent",

}

TY - PAT

T1 - Immunosuppressive glycoforms of soluble CD52

AU - Harrison, Leonard Charles

AU - Bandala-Sanchez, Esther

AU - Goddard-Borger, Ethan David

AU - Packer, Nicolle Hannah

AU - Mansour, Shathili Abdulrahman

N1 - Designated States: AL, AT, BA, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

PY - 2022/1/12

Y1 - 2022/1/12

N2 - The present disclosure relates to glycoprotein CD52 and fusion proteins thereof, wherein the CD52 glycoprotein has α-2,3-sialylated N-glycans, O-glycosylation and a pI of about 5 to about 6. The disclosure further relates to the preparation and purification of these proteins and their use in the suppression of effector T-cell function and/or immune response, such as in the treatment of diseases or conditions mediated by effector T-cell function.

AB - The present disclosure relates to glycoprotein CD52 and fusion proteins thereof, wherein the CD52 glycoprotein has α-2,3-sialylated N-glycans, O-glycosylation and a pI of about 5 to about 6. The disclosure further relates to the preparation and purification of these proteins and their use in the suppression of effector T-cell function and/or immune response, such as in the treatment of diseases or conditions mediated by effector T-cell function.

M3 - Patent

M1 - EP3935073

ER -

Immunosuppressive glycoforms of soluble CD52

Abstract

Bibliographical note

Access to Document

Fingerprint

Research output